MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.390
+0.010
+0.72%
Closed 16:13 11/13 EST
OPEN
1.380
PREV CLOSE
1.380
HIGH
1.420
LOW
1.370
VOLUME
54.52K
TURNOVER
--
52 WEEK HIGH
6.33
52 WEEK LOW
1.280
MARKET CAP
66.99M
P/E (TTM)
-0.8739
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SELB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SELB News

  • Edited Transcript of SELB earnings conference call or presentation 8-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11h ago
  • Selecta Biosciences to Present at the Stifel 2019 Healthcare Conference
  • GlobeNewswire.1d ago
  • Selecta Biosciences, Inc. (SELB) CEO Carsten Brunn on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.2d ago
  • Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout
  • GlobeNewswire.2d ago

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About SELB

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
More

Webull offers Selecta Biosciences Inc (SELB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.